Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Immune System Regulator Allows Inflammatory Response While Preventing Autoimmune Attack

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Print article
Image: Schematic of balance between tolerance and inflammation mediated by BACH2 (Photo courtesy of the US National Institutes of Health).
Image: Schematic of balance between tolerance and inflammation mediated by BACH2 (Photo courtesy of the US National Institutes of Health).
The BACH2 (BTB and CNC homology 1, basic leucine zipper transcription factor 2) gene was shown recently to encode for a protein that acts as a master immune system regulator by enabling inflammatory response to disease causing agents on the one hand and by preventing a hyper-inflammatory response and autoimmune attack on the other.

Genetic polymorphisms within a single locus encoding the BACH2 transcription factor are associated with numerous autoimmune and allergic diseases including asthma, Crohn’s disease, celiac disease, vitiligo, multiple sclerosis, and type I diabetes. The BACH2 protein is normally found on the surface of CD4+ T-cells. These cells play a dual role within the immune system with some populations of CD4+ T-cells activating immune responses, while others, regulatory T-cells (Tregs), function to limit immune responses. An in-depth study of how the BACH2 regulatory factor controls the balance between the two types of immune response was conducted by investigators at the [US] National Institutes of Health (Bethesda, MD, USA).

The investigators worked with a genetically engineered mouse line that permitted silencing or activation of BACH2. They found that the loss of the BACH2 gene in CD4+ T-cells caused them to become inflammatory, even in situations that would normally result in the formation of protective regulatory cells. Mice lacking the BACH2 gene generated large numbers of inflammatory cells, and the animals died of autoimmune diseases within the first few months of life. Insertion of the BACH2 gene via gene therapy into BACH2-deficient cells restored their ability to produce regulatory cells.

"Although genes have been found that play specific roles in either inflammatory cells or regulatory cells, BACH2 regulates the choice between the two cell types, resulting in its critical role in maintaining the immune system’s healthy balance," said senior author Dr. Nicholas P. Restifo, an investigator at the [US] National Institutes of Health. "It is apt that the gene shares its name with the famous composer Bach, since it orchestrates many components of the immune response, which, like the diverse instruments of an orchestra, must act in unison to achieve symphonic harmony."

The study was published in the June 2, 2013, online edition of the journal Nature.

Related Links:

[US] National Institutes of Health



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.